Brief: Foghorn Therapeutics Provides Update On FHD-609

Foghorn Therapeutics

24/04/2023 12:27

April 24 (Reuters) - Foghorn Therapeutics Inc.  FHTX.O :
    * FOGHORN THERAPEUTICS PROVIDES AN UPDATE ON FHD-609
    * FOGHORN THERAPEUTICS INC. - PAUSING ENROLLMENT IN FHD-609
STUDY
IN SYNOVIAL SARCOMA AND SMARCB1-DELETED TUMORS
    * FOGHORN THERAPEUTICS - PAUSING ENROLLMENT DUE TO A GRADE 4
QTC
PROLONGATION EVENT IN A SYNOVIAL SARCOMA PATIENT AT SECOND
HIGHEST DOSE
    * FOGHORN THERAPEUTICS - ENROLLMENT OF DOSE ESCALATION
PORTION OF
FHD-609 STUDY HAS BEEN COMPLETED AND A MAXIMUM TOLERATED DOSE
HAS BEEN IDENTIFIED
    * FOGHORN THERAPEUTICS - PATIENTS IN AFFECTED COHORT WERE
DOSE
REDUCED & ADDITIONAL SAFETY MEASURES DISCUSSED WITH & PROVIDED
TO STUDY INVESTIGATORS
    * FOGHORN THERAPEUTICS INC. - FDA PLACED FHD-609 STUDY ON
PARTIAL
CLINICAL HOLD IN UNITED STATES
    * FOGHORN THERAPEUTICS - FDA ALLOWING PATIENTS CURRENTLY
ENROLLED
AND BENEFITING FROM THERAPY TO CONTINUE DOSING AND TO REMAIN ON
FHD-609
    * FOGHORN THERAPEUTICS INC. - NOT AT THIS TIME PLANNING TO
PURSUE
A DOSE EXPANSION STUDY INDEPENDENTLY

Source text for Eikon:  ID:nGNX2zZ7Y6 
Further company coverage:  FHTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))